| Texto completo | |
| Autor(es): |
Dutra, Jocely L.
;
Honorato, Joao
;
Graminha, Angelica
;
Moraes, Carlos Andre F.
;
de Oliveira, Kleber T.
;
Cominetti, Marcia R.
;
Castellano, Eduardo E.
;
Batista, Alzir A.
Número total de Autores: 8
|
| Tipo de documento: | Artigo Científico |
| Fonte: | DALTON TRANSACTIONS; v. 53, n. 47, p. 15-pg., 2024-06-14. |
| Resumo | |
Palladium(II) complexes have stimulated research interest mainly due to their in vitro cytotoxicity against various cancer cell lines and their low cytotoxicity in healthy cells. Thus, in this work, we combined Pd(II)/phosphine systems with the natural product curcumin as a ligand, obtaining a series of complexes, [Pd(cur)(PPh3)(2)]PF6 (A1), [Pd(cur)(dppe)]PF6 (A2), [Pd(cur)(dppp)]PF6 (A3), [Pd(cur)(dppb)]PF6 (A4) and [Pd(cur)(dppf)]PF6 (A5), where dppe = 1,2-bis(diphenylphosphino)ethane, dppp = 1,3-bis(diphenylphosphino)propane, dppb = 1,4-bis(diphenylphosphino)butane, and dppf = 1,1 '-bis(diphenylphosphino)ferrocene (P-P), which were characterized by elemental analysis, molar conductivity analysis, and mass, NMR (H-1, C-13, P-31{H-1}), UV-vis, and IR spectroscopies, and four of them (A1, A2, A4, and A5) by X-ray crystallography. The in vitro cell viability of the complexes A1-A5, cisplatin, and the free ligand curcumin against MDA-MB-231 (human triple-negative breast tumor cells), SK-BR-3 (human breast tumor cells), A549 (human lung tumor cells), MRC-5 (non-tumor human lung cells), A2780 (human ovarian carcinoma cells), and A2780cis (cisplatin-resistant human ovarian carcinoma cells), was evaluated by the MTT colorimetric assay. For the tumor cell lines tested, the complexes showed good anticancer activities. The results showed that in general the complexes had lower IC50 values than free curcumin and the precursors [PdCl2(P-P)]. IC50 results obtained for the A1-A5 complexes, in the MCF-7 cell line, are similar to those that had already been observed for some Pd/bipy/curcumin complexes. In the MDA-MB-231 cell line, complexes A1 and A5 stood out, with their lowest IC50 values, around 5 mu mol L-1, and the complexes appeared to be more active (lower IC50 values) against the ovarian cell lines. Complex A1 was 23 and 22-fold more cytotoxic than cisplatin, against the A2780 and A2780cis cells, respectively. The complex A1 was studied on A2780cis cells and it was found that this complex inhibits colony formation and induces cell cycle arrest in the sub-G1 phase in a concentration-dependent manner and leads to cell death by apoptosis. The DCFDA assay revealed a potent ROS induction for complex A1. (AU) | |
| Processo FAPESP: | 21/02522-0 - EMU Concedido no processo 2017/15850-0: Synergy-S |
| Beneficiário: | Eduardo Ernesto Castellano |
| Modalidade de apoio: | Auxílio à Pesquisa - Programa Equipamentos Multiusuários |
| Processo FAPESP: | 17/15850-0 - Difração de raios X como ferramenta no desenvolvimento de potenciais fármacos |
| Beneficiário: | Eduardo Ernesto Castellano |
| Modalidade de apoio: | Auxílio à Pesquisa - Temático |
| Processo FAPESP: | 21/04876-4 - Estudos sobre estrutura & atividade de complexos de RuII/areno/mercaptoligantes frente ao câncer |
| Beneficiário: | João Honorato de Araujo Neto |
| Modalidade de apoio: | Bolsas no Brasil - Pós-Doutorado |
| Processo FAPESP: | 23/02475-8 - Complexos fosfínicos de Ru(II) com naftoquinonas e derivados: potenciais anticancerígenos, estudos in vitro e in vivo |
| Beneficiário: | Alzir Azevedo Batista |
| Modalidade de apoio: | Auxílio à Pesquisa - Regular |